Trial Profile
Long-Term Outocomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ORIGAMI Study
- Sponsors Bristol-Myers K.K.
- 05 Jun 2021 Results (n=270) of post-hoc analysis evaluating factors associated with the effectiveness of Abatacept, presented at the 22nd Annual Congress of the European League Against Rheumatism
- 13 May 2019 Planned End Date changed from 30 Sep 2023 to 31 Oct 2023.
- 13 May 2019 Status changed from recruiting to active, no longer recruiting.